Suparshva Pharma Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 22-12-2024
- Paid Up Capital ₹ 1.00 M
as on 22-12-2024
- Company Age 14 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 9.00 M
as on 22-12-2024
- Revenue -89.18%
(FY 2015)
- Profit -86.00%
(FY 2015)
- Ebitda -170.72%
(FY 2015)
- Net Worth 2.70%
(FY 2015)
- Total Assets -84.76%
(FY 2015)
About Suparshva Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹9.00 M.
Ashwin Shantilal, Bhaumik Shah, Ankit Shah, and One other member serve as directors at the Company.
- CIN/LLPIN
U74999MH2010PTC203832
- Company No.
203832
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Jun 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Suparshva Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhaumik Shah  | Director | 08-Jun-2010 | Current |
| Ankit Shah | Director | 03-Dec-2010 | Current |
| Ashwin Shantilal | Director | 08-Jun-2010 | Current |
| Nikesh Parekh | Director | 08-Jan-2011 | Current |
Financial Performance of Suparshva Pharma.
Suparshva Pharma Private Limited, for the financial year ended 2015, experienced significant reduction in revenue, with a 89.18% decrease. The company also saw a substantial fall in profitability, with a 86% decrease in profit. The company's net worth moved up by a moderate rise of 2.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Suparshva Pharma?
In 2017, Suparshva Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
S. Parikh Pharma Private LimitedActive 16 years 2 monthsAshwin Shantilal, Bhaumik Shah and 2 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Vasai Vikas Sahakari Bank Ltd Creation Date: 10 Oct 2011 | ₹9.00 M | Open |
How Many Employees Work at Suparshva Pharma?
Unlock and access historical data on people associated with Suparshva Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Suparshva Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Suparshva Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
